118 related articles for article (PubMed ID: 12708613)
1. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments.
Corley RA; Mast TJ; Carney EW; Rogers JM; Daston GP
Crit Rev Toxicol; 2003; 33(2):137-211. PubMed ID: 12708613
[TBL] [Abstract][Full Text] [Related]
2. Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling.
Gao X; Diep JK; Norris DA; Yu RZ; Geary RS
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):979-990. PubMed ID: 37970635
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-based pharmacokinetic models to predict drug exposure during pregnancy.
Ait-Chikh C; Page G; Thoreau V
Ann Pharm Fr; 2024 Mar; 82(2):236-242. PubMed ID: 37739215
[TBL] [Abstract][Full Text] [Related]
4. The MPRINT Hub Data, Model, Knowledge and Research Coordination Center: Bridging the gap in maternal-pediatric therapeutics research through data integration and pharmacometrics.
Quinney SK; Bies RR; Grannis SJ; Bartlett CW; Mendonca E; Rogerson CM; Backes CH; Shah DK; Tillman EM; Costantine MM; Aruldhas BW; Allam R; Grant A; Abbasi MY; Kandasamy M; Zang Y; Wang L; Shendre A; Li L
Pharmacotherapy; 2023 May; 43(5):391-402. PubMed ID: 36625779
[TBL] [Abstract][Full Text] [Related]
5. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment.
Tan YM; Clewell H; Campbell J; Andersen M
Int J Environ Res Public Health; 2011 May; 8(5):1613-30. PubMed ID: 21655141
[TBL] [Abstract][Full Text] [Related]
6. Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure.
Hudson RE; Metz TD; Ward RM; McKnite AM; Enioutina EY; Sherwin CM; Watt KM; Job KM
Front Pharmacol; 2023; 14():1111601. PubMed ID: 37033628
[TBL] [Abstract][Full Text] [Related]
7. Utility of life stage-specific chemical risk assessments based on New Approach Methodologies (NAMs).
Gonnabathula P; Choi MK; Li M; Kabadi SV; Fairman K
Food Chem Toxicol; 2024 Jun; 190():114789. PubMed ID: 38844066
[TBL] [Abstract][Full Text] [Related]
8. A Summary Report of FSCJ Workshop "Future Challenges and Opportunities in Developing Methodologies for Improved Human Risk Assessments".
Tachibana K; Kass GEN; Ono A; Yamada T; Tong W; Doerge DR; Yamazoe Y
Food Saf (Tokyo); 2019 Dec; 7(4):83-89. PubMed ID: 31998592
[TBL] [Abstract][Full Text] [Related]
9. Application of physiologically based pharmacokinetic models in chemical risk assessment.
Mumtaz M; Fisher J; Blount B; Ruiz P
J Toxicol; 2012; 2012():904603. PubMed ID: 22523493
[TBL] [Abstract][Full Text] [Related]
10. In utero priming of fetal immune activation: Myths and mechanisms.
Vidal MS; Menon R
J Reprod Immunol; 2023 Jun; 157():103922. PubMed ID: 36913842
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based mathematical models of nanomaterials for regulatory toxicology: A review.
Lamon L; Asturiol D; Vilchez A; Cabellos J; Damásio J; Janer G; Richarz A; Worth A
Comput Toxicol; 2019 Feb; 9():133-142. PubMed ID: 31008415
[TBL] [Abstract][Full Text] [Related]
12. The need for non- or minimally-invasive biomonitoring strategies and the development of pharmacokinetic/pharmacodynamic models for quantification.
Timchalk C; Weber TJ; Smith JN
Curr Opin Toxicol; 2017 Jun; 4():28-34. PubMed ID: 35978611
[TBL] [Abstract][Full Text] [Related]
13. Moving towards a holistic approach for human health risk assessment - Is the current approach fit for purpose?
Bennekou SH
EFSA J; 2019 Jul; 17(Suppl 1):e170711. PubMed ID: 32626448
[TBL] [Abstract][Full Text] [Related]
14. Advancing the understanding of children's digital engagement: responsive methodologies and ethical considerations in psychological research.
Kucirkova N; Livingstone S; Radesky J
Front Psychol; 2024; 15():1285302. PubMed ID: 38716271
[TBL] [Abstract][Full Text] [Related]
15. More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation.
Desai G; Babu GN; Rajkumar RP; Chandra PS
Indian J Psychiatry; 2009 Jan; 51(1):26-33. PubMed ID: 19742205
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic and Safety Evaluation During Pregnancy and Lactation].
Fujioka I; Murashima A
Brain Nerve; 2023 Sep; 75(9):993-998. PubMed ID: 37691239
[TBL] [Abstract][Full Text] [Related]
17. Selection of a suitable animal model to evaluate secretion of drugs in the human milk: a systematic approach.
Nilkant R; Kathiresan C; Kumar N; Caritis S; Shaik IH; Venkataramanan R
Xenobiotica; 2024 Jun; ():1-16. PubMed ID: 38634455
[TBL] [Abstract][Full Text] [Related]
18. Data-driven predictive modeling in risk assessment: Challenges and directions for proper uncertainty representation.
Stødle K; Flage R; Guikema SD; Aven T
Risk Anal; 2023 Dec; 43(12):2644-2658. PubMed ID: 36958984
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling in Pregnancy, during Lactation and in Neonates: Achievements, Challenges and Future Directions.
Allegaert K; Quinney SK; Dallmann A
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675161
[TBL] [Abstract][Full Text] [Related]
20. Investigating open access new approach methods (NAM) to assess biological points of departure: A case study with 4 neurotoxic pesticides.
Silva MH
Curr Res Toxicol; 2024; 6():100156. PubMed ID: 38404712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
